Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -301.82% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 1.21% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -17.09% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 13.91% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 31.67% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 388.06% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn | 1,169.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,169.30% |
| Mar 31, 2026 | -1,944,998.80% |
| Dec 31, 2025 | 1,003.53% |
| Sep 30, 2025 | 190.49% |
| Jun 30, 2025 | 139.53% |
| Mar 31, 2025 | 100.09% |
| Dec 31, 2024 | 59.64% |
| Sep 30, 2024 | 64.42% |
| Jun 30, 2024 | 84.59% |
| Mar 31, 2024 | 39.32% |
| Dec 31, 2023 | 16.54% |
| Sep 30, 2023 | 16.54% |
| Jun 30, 2023 | -25.60% |
| Mar 31, 2023 | 29.50% |
| Dec 31, 2022 | -287.69% |
| Sep 30, 2022 | 30.44% |
| Jun 30, 2022 | -30.76% |
| Mar 31, 2022 | 99.99% |
| Dec 31, 2021 | 75.20% |
| Sep 30, 2021 | 88.22% |